Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart C Gordon

Showing results (181-190 of 214) with videos related to

Pageof 22
Sort By:
Lancet (London, England)|August 10, 2010
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialPaul Y Kwo, Eric J Lawitz, Jonathan McCone, et al.
The American Journal of Gastroenterology|January 28, 2020
Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary CholangitisStuart C Gordon, Kuan-Han Hank Wu, Keith Lindor, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 30, 2015
All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C VirusFujie Xu, Anne C Moorman, Xin Tong, et al.
Journal of Hepatology|August 12, 2018
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patientsChristoph Sarrazin, Curtis L Cooper, Michael P Manns, et al.
Digestive Diseases and Sciences|September 9, 2021
Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USAJia Li, Mei Lu, Yueren Zhou, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1Marc Bourlière, Stuart C Gordon, Eugene R Schiff, et al.
Lancet (London, England)|March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialKris V Kowdley, Eric Lawitz, Israel Crespo, et al.
The American Journal of Gastroenterology|June 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study ResultsCynthia Levy, Palak J Trivedi, Kris V Kowdley, et al.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Hepatology Communications|January 29, 2024
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitisMaryam Yazdanfar, Joseph Zepeda, Richard Dean, et al.
Pageof 22

Showing results (181-190 of 214) with videos related to

Sort By:
Pageof 22
Lancet (London, England)|August 10, 2010
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialPaul Y Kwo, Eric J Lawitz, Jonathan McCone, et al.
The American Journal of Gastroenterology|January 28, 2020
Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary CholangitisStuart C Gordon, Kuan-Han Hank Wu, Keith Lindor, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 30, 2015
All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C VirusFujie Xu, Anne C Moorman, Xin Tong, et al.
Journal of Hepatology|August 12, 2018
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patientsChristoph Sarrazin, Curtis L Cooper, Michael P Manns, et al.
Digestive Diseases and Sciences|September 9, 2021
Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USAJia Li, Mei Lu, Yueren Zhou, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1Marc Bourlière, Stuart C Gordon, Eugene R Schiff, et al.
Lancet (London, England)|March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialKris V Kowdley, Eric Lawitz, Israel Crespo, et al.
The American Journal of Gastroenterology|June 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study ResultsCynthia Levy, Palak J Trivedi, Kris V Kowdley, et al.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Hepatology Communications|January 29, 2024
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitisMaryam Yazdanfar, Joseph Zepeda, Richard Dean, et al.
Pageof 22